Mauna Kea Technologies : Business at a standstill in Q2, why this is a strong opportunity
>Q2 wiped out by COVID-19 - Mauna Kea has reported Q2 2020 sales. With € 0.6m of sales recorded, i.e. business down -72% relative to the corresponding period of 2019, this quarter is the consequence of activity virtually grinding to a standstill and the postponement of non-essential procedures in hospitals following the COVID-19 pandemic. Q2 2020 is therefore a lost quarter which does not allow us to judge the company’s performance. The key question is therefore: once...Mauna Kea Technologies is a global medical device company based in France. Co. is focused on innovations in the field of endomicroscopy (microscopic imaging during endoscopy procedures). Co. is predominately active in the advent of optical biopsy. Co. researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Co.'s flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Co. has marketing authorizations in Thailand, United Kingdom, U.S., Brazil, Chile, South Korea, Poland, Russia and Saudi Arabia.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.